Intriguingly, a combination of low/medium TRAIL-R1 level and high TRAIL-R3 level in primary colorectal carcinoma cells expressing p53 is associated with a poor response to 5-FU-based chemotherapy and with shorter progression-free survival [43]. This evidence concerns the gene TNFRSF10A and colorectal carcinoma.